Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.11
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 14, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 30, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 20, 24 | Evercore ISI Group | downgrade | Outperform | In Line |
| Dec 2, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 18, 24 | TD Cowen | downgrade | Buy | Hold |
| Nov 4, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 3, 24 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Aug 6, 24 | TD Cowen | upgrade | Hold | Buy |
| Aug 6, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 43.38 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 28.15 | Oscillator | Neutral |
| Williams %R (14) | -86.67 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.02 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.97 (+DI 25.6 / -DI 19.7) | Trend | Buy |
| EMA 20 | 1.16 | MA | Strong Sell |
| SMA 20 | 1.17 | MA | Strong Sell |
| EMA 50 | 1.25 | MA | Strong Sell |
| SMA 50 | 1.19 | MA | Strong Sell |
| SMA 200 | 2.02 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 3, 26 | Zack Debra | officer: Chief Medical Officer | A-Award | 324,675 @ $1.54 | $500.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | SPRO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 7.9x | 2.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.9x | EPS est. -0.58 | Discount |
| Price / Book | 1.5x | 2.1x | Discount |
| Price / Sales | 1.5x | 33.3x | Discount |
| EV / EBITDA | 2.1x | 1.4x | Elevated |
| Return on equity | 16.2% | — | Healthy |
| Gross margin | 100.0% | 49.8% | Above hist. |
| Debt / Equity | 0.05 | 0.07 | Conservative |
| Piotroski / Altman Z | 6/9 | Z -5.61 | Distress |
Discounted cash flow model
| Aug 3, 26 |
| Zack Debra |
| officer: Chief Medical Officer |
| A-Award |
| 162,311 |
| — |
| Aug 3, 26 | Zack Debra | 0 | — |
| Jun 23, 26 | Deshpande Milind | director | A-Award | 10,000 | — |
| Jun 23, 26 | Deshpande Milind | director | A-Award | 20,000 @ $2.15 | $43.00K |
| Jun 23, 26 | Tregoning Kathleen | director | A-Award | 10,000 | — |
| Jun 23, 26 | Tregoning Kathleen | director | A-Award | 20,000 @ $2.15 | $43.00K |
| Jun 23, 26 | Smith Cynthia | director | A-Award | 10,000 | — |
FY2025 · 10-K disclosure
Stock news · updated daily
Spero Therapeutics NASDAQ: SPRO plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief Executive Officer Esther Rajavelu said during a company presentation.
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero's new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C.
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.17 | -0.16 | Beat 5.9% | — |
| May 13, 2026 | -0.18 | -0.13 | Beat 27.8% | $258.0K |
| Mar 26, 2026 | -0.20 | 0.53 | Beat 365.0% | $41.30M |
| Nov 13, 2025 | -0.25 | -0.13 | Beat 48.0% | $3.05M |
| Aug 12, 2025 | -0.38 | -0.03 | Beat 92.1% | $11.80M |
| May 13, 2025 | -0.55 | -0.25 | Beat 54.5% | $5.87M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| EFFECT | Sep 10, 2026 | 2026-09-11 00:15:09 | View |
| 8-K | Aug 28, 2026 | 2026-08-28 17:25:56 | View |
| S-3 | Aug 28, 2026 | 2026-08-28 17:04:22 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 16:09:26 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:03:20 | View |
| 4 | Aug 6, 2026 | 2026-08-06 18:49:22 | View |
| 3 | Aug 6, 2026 | 2026-08-06 18:41:50 | View |
| 8-K | Jul 14, 2026 | 2026-07-14 06:30:09 | View |
| 4 | Jun 25, 2026 | 2026-06-25 19:26:49 | View |
| 4 | Jun 25, 2026 | 2026-06-25 19:17:12 | View |
Proxy statement (DEF 14A) disclosures